

REGADO BIOSCIENCES COMPLETES \$20 MILLION SERIES B FINANCING

Research Triangle Park, NC, August 12, 2005 - Regado Biosciences, Inc., a drug development company focused on the development of antidote-controlled antithrombotics, announced today the completion of a \$20 million Series B financing co-led by Domain Associates of Princeton, NJ, and Quaker BioVentures of Philadelphia, PA. Also participating in the round was the Aurora Funds of Durham, NC, which provided seed funding for the Company and led the Series A financing, as well as individual investors. "Aurora is quite pleased to be working with Domain and Quaker on Regado," commented Jeff Clark, Managing General Partner for the Aurora Funds.

In conjunction with the close of the financing Jesse Treu, General Partner of Domain Associates and P. Sherrill Neff, Managing Partner of Quaker BioVentures, have joined the Company's Board of Directors. "The Regado drug-antidote technology is truly novel," noted Jesse Treu, who will serve as the Company's Chairman, "and the Company's initial program has the ability to transform anticoagulant therapy."

"This financing provides further validation of the Regado technology and will allow us to build on the progress generated to date," commented Regado's CEO Douglas Gooding. "Domain and Quaker both have invaluable experience growing emerging companies and a proven track record of success. We are excited to have them involved with the Company as we enter this next phase of growth."

"For Quaker BioVentures, Regado Biosciences exemplifies our regionally-focused investment strategy," said P. Sherrill Neff, "cutting-edge technology out of Duke University, local investment guidance from Aurora, and talented young entrepreneurs - all coupled with a product in an important area of medicine that appears to have significant advantages over current products and other products in development."

About Regado Biosciences

Regado is a spin-out of the Department of Surgery at Duke University Medical Center. Regado's technology enables the rational design of drug-antidote pairs against any target accessible to the bloodstream. The Company's lead product, REG1, is the first specific, direct acting, antidote-controlled anticoagulant. Regado is developing the REG1 anticoagulation system as an antidote-reversible anticoagulant for use in coronary revascularization procedures (CABG and PCI), for use in patients suffering from acute coronary syndromes, and potentially as an anticoagulant for other indications in which it would be advantageous to employ an antidote-reversible agent for anticoagulant or antithrombotic therapy (e.g., DVT and VTE).

About Domain Associates

Founded in 1985, Domain Associates, L.L.C. is a venture capital firm with an exclusive focus on life sciences. With \$1.4 billion of capital under management, Domain is headquartered in Princeton, NJ, with a second office in Laguna Niguel, CA. Domain's three major investment segments are pharmaceuticals, specialty pharmaceuticals, and medical devices, while additional areas of interest include biomaterials,

bioinstrumentation, and diagnostics. The General Partners of Domain have a total of close to 200 person-years of experience among them in the healthcare/venture capital industries and have been involved in the formation and growth of more than 170 life-sciences companies. The highly focused network, experience, and reputation of this team have made it one of the top private-equity groups participating in the healthcare field.

About Quaker BioVentures

Quaker BioVentures is a venture capital firm dedicated to investing in life science companies located in the Mid-Atlantic region. The firm leads investments in companies across the spectrum of the life science industry, including biopharmaceuticals, medical devices, human diagnostics, health information technology, and healthcare services. Quaker BioVentures invests in companies at varying stages of development, from early stage businesses to public companies. Quaker BioVentures manages approximately \$280 million in capital.

About The Aurora Funds

Founded in 1994, The Aurora Funds is a venture capital firm that provides capital and strategic help to entrepreneurs with early stage life sciences and information technology companies in the Southeastern and mid-Atlantic United States. The firm has more than \$155 million of total capital under management and is currently investing out of its fourth fund of \$85 million. The firm has the capacity to invest between \$4 million and \$7 million throughout the life cycle of an investment.